Figure 6.Kaplan-Meier estimate of 12-year cancer-specific survival (CSS: A) and progression-free survival (PFS: B) of ccRCC patients according to different PTX3 serum levels at baseline.
Figure 6 — PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma | Aging
